Personalized vaccines are an innovative strategy in cancer immunotherapy aimed at provoking a patient's immune system to see and destroy tumor-specific antigens. The session "Personalized Vaccines" is dedicated to the development, clinical utility, and potential of these customized treatments.".
In contrast to conventional vaccines, individualized cancer vaccines are designed to fit the distinct molecular portrait of an individual's tumor, typically targeting neoantigens produced by tumor-specific mutations. By stimulating T cells against such antigens, individualized vaccines can induce a specific and potent immune response, with minimal harm to normal tissues. Progress in genomic sequencing, bioinformatics, and immunology has facilitated high-speed identification of candidate antigens and the development of bespoke vaccine preparations.
The session discusses various vaccine platforms, such as peptide-based, mRNA-based, and dendritic cell-based vaccines, and their combination with checkpoint inhibitors or other immunotherapies to maximize efficacy. Various clinical trials have produced encouraging outcomes, including tumor regression and enhanced survival in various malignancies.
Participants will learn about the principles, design strategies, and therapeutic promise of personalized vaccines. This session highlights how person-specific immunization strategies are revolutionizing cancer therapy, providing targeted, effective, and patient-customized solutions that drive the era of precision oncology.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
